Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) play a role in the processes of extracellular matrix degradation. Changes in their expression levels have been observed in various tumor types, including lung carcinoma. However, their clinical significance and their prognostic importance in the progression of nonsmall cell lung carcinoma (NSCLC) remain to be specified. In this study, mRNA expression levels of MMP‐1, MMP‐9, TIMP‐1, and TIMP‐2 were evaluated in patients with resected NSCLC, and their associations with disease progression and prognosis were determined.

[1]  W. Mutschler,et al.  Prognostic impact of matrix metalloproteinase‐9 in operable non‐small cell lung cancer , 2003, International journal of cancer.

[2]  S. Apte,et al.  The Gene Structure of Tissue Inhibitor of Metalloproteinases (TIMP)-3 and Its Inhibitory Activities Define the Distinct TIMP Gene Family (*) , 1995, The Journal of Biological Chemistry.

[3]  J. Carmichael,et al.  Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. , 1993, Journal of the National Cancer Institute.

[4]  Nithya Ramnath,et al.  Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Aust,et al.  Differential Expression and Activity Status of MMP-1, MMP-2 and MMP-9 in Tumor and Stromal Cells of Squamous Cell Carcinomas of the Lung , 2002, Tumor Biology.

[6]  A. Eisen,et al.  Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. , 1991, The Journal of investigative dermatology.

[7]  John O'Quigley,et al.  An application of changepoint methods in studying the effect of age on survival in breast cancer , 1999 .

[8]  C. Bucana,et al.  Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  K. O'Byrne,et al.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer , 1999, Thorax.

[10]  W. Mutschler,et al.  Overexpression of Matrix Metalloproteinase 2 Predicts Unfavorable Outcome in Early-Stage Non-Small Cell Lung Cancer 1 , 2000 .

[11]  G. Li,et al.  Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. , 1999, Cancer research.

[12]  L. Liotta,et al.  Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. , 1989, The Journal of biological chemistry.

[13]  P. Saldiva,et al.  Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  W. Stetler-Stevenson,et al.  Structural biochemistry and activation of matrix metalloproteases. , 1993, Current opinion in cell biology.

[15]  W. Stetler-Stevenson,et al.  The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. , 1994, The European respiratory journal.

[16]  D. Gomez,et al.  Mammary carcinoma cells over‐expressing tissue inhibitor of metalloproteinases‐1show vascular endothelial growth factor expression , 1998 .

[17]  D. Belin,et al.  Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. , 1987, Cancer research.

[18]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[19]  A. Karameris,et al.  Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study. , 1997, American journal of respiratory and critical care medicine.

[20]  F. Hirahara,et al.  Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. , 1997, Human pathology.

[21]  M. Copin,et al.  Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  W. Stetler-Stevenson,et al.  In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. , 1998, The Journal of clinical investigation.

[23]  I. Lubensky,et al.  Localization of the 92 kd gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization. , 1994, The American journal of pathology.

[24]  J. Risteli,et al.  Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  R. Khokha,et al.  Differential expression of matrix metalloproteinases and their inhibitors in non‐small cell lung cancer , 2000, The Journal of pathology.

[26]  C. Mountain,et al.  Regional lymph node classification for lung cancer staging. , 1997, Chest.

[27]  D. Gomez,et al.  Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. , 1998, International journal of cancer.

[28]  K. Iwata,et al.  Growth‐promoting activity of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) for a wide range of cells A possible new growth factor in serum , 1992, FEBS letters.

[29]  M. Polette,et al.  Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: Quantificative and morphological analyses , 1997, International Journal of Cancer.

[30]  J. Hodgson,et al.  TIMP-1 Alters Susceptibility to Carcinogenesis , 2004, Cancer Research.

[31]  A. Strongin,et al.  Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. , 1992, The Journal of biological chemistry.

[32]  E. Brown,et al.  Molecular characterization and expression of the gene encoding human erythroid-potentiating activity , 1985, Nature.

[33]  P. Zimmerman,et al.  TIMP1 and adverse prognosis in non-small cell lung cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  P. Stephens,et al.  Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity , 1985, Nature.

[35]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[36]  E. Brambilla,et al.  Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. , 1997, The American journal of pathology.

[37]  W. Kisiel,et al.  Coexisting macrophage‐associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues , 1991, Cancer.

[38]  I. Goldberg,et al.  Complex roles of tissue inhibitors of metalloproteinases in cancer , 2002, Oncogene.

[39]  M. Shipp,et al.  Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. , 1995, Cancer research.

[40]  V. Gouyer,et al.  Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. , 1995, The American journal of pathology.

[41]  A. Kossakowska,et al.  Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. , 1992, British Journal of Cancer.

[42]  K. Brew,et al.  Tissue inhibitors of metalloproteinases: evolution, structure and function. , 2000, Biochimica et biophysica acta.

[43]  H. McLeod,et al.  Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. , 2001, Oncology reports.

[44]  K. Yasumoto,et al.  Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung , 1997, Pathology international.

[45]  D. Harpole,et al.  Molecular biologic substaging of stage I lung cancer according to gender and histology. , 2000, The Annals of thoracic surgery.